Anti-IL-23p19 therapy inhibits the adoptive transfer of syngeneic graft-versus-host disease |
| |
| Authors: | J. Anthony Brandon C. Darrell Jennings Alan M. Kaplan J. Scott Bryson |
| |
| Affiliation: | 1. Departments of Microbiology, Immunology and Molecular Genetics, University of Kentucky Medical Center, Lexington, KY 40536, USA;2. Pathology, University of Kentucky Medical Center, Lexington, KY, USA;3. Internal Medicine, Division of Hematology and Blood & Marrow Transplantation, University of Kentucky Medical Center, Lexington, KY, USA;4. Markey Cancer Center, University of Kentucky Medical Center, Lexington, KY, USA |
| |
| Abstract: | Syngeneic graft-versus-host disease (SGVHD), a chronic inflammatory disease, develops following irradiation, syngeneic bone marrow transplantation (BMT) and treatment with the immunosuppressive agent cyclosporine A (CsA). We have shown that TH1 and TH17 cytokine responses are increased during the development of SGVHD. The current study was designed to further investigate the involvement of TH17 immunity in SGVHD-associated colitis. IL-23 is a TH17 cytokine responsible for maintaining the effector functions of TH17 cells. The administration of anti-mouse IL-23p19 was shown to significantly reduce the clinical symptoms of primary and secondary SGVHD-associated colitis resulting in a significant reduction in both TH1 and TH17 associated cytokine expression. These results demonstrate that the TH17-associated cytokine, IL-23, may prove to be a beneficial therapeutic target in the treatment of chronic colon inflammation. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
